BMP2 has been specifically associated with the migratory and invasive capacity of prostate and liver cancer cells in vitro [57,58,59], while the BMP antagonist, Noggin, inhibits the migration of BMP2-stimulated prostate cancer cells [60,61]. This evidence concerns the gene NOG and prostate carcinoma.